| Human immunodeficiency virus I infection
Apretude vs Juluca
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Apretude vs Juluca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJuluca has a higher rate of injection site reactions vs Apretude based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Juluca but not Apretude, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Apretude
Juluca
At A Glance
IM injection
Every 2 months
HIV integrase strand transfer inhibitor
Oral
Once daily
INSTI/NNRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 600-mg (3-mL) gluteal IM initiation injections 1 month apart for 2 consecutive months, then 600-mg (3-mL) every 2 months; optional oral lead-in with cabotegravir 30 mg once daily for at least 28 days prior to first injection.
Human immunodeficiency virus I infection One tablet (dolutegravir 50 mg/rilpivirine 25 mg) orally once daily with a meal; if coadministered with rifabutin, take an additional rilpivirine 25-mg tablet with JULUCA once daily with a meal for the duration of rifabutin coadministration.
Contraindications
- Unknown or positive HIV-1 status
- Previous hypersensitivity reaction to cabotegravir
- Coadministration with anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin) due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
- Coadministration with antimycobacterials rifampin or rifapentine due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
- Previous hypersensitivity reaction to dolutegravir or rilpivirine
- Coadministration with dofetilide
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with systemic dexamethasone (more than a single-dose treatment)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
Adverse Reactions
Most common (>=1%) Injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, upper respiratory tract infection
Serious Hypersensitivity reactions, hepatotoxicity, depressive disorders including depression, suicidal ideation, and suicide attempt
Postmarketing Hypersensitivity reactions (angioedema, urticaria), Stevens-Johnson syndrome/toxic epidermal necrolysis
Most common (>=2%) Diarrhea, headache, nausea
Serious Depressive disorders including suicidal ideation, hepatotoxicity, skin and hypersensitivity reactions
Postmarketing Acute liver failure, hepatotoxicity, weight increase, arthralgia, myalgia, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Pharmacology
Cabotegravir is an HIV integrase strand transfer inhibitor (INSTI) that inhibits HIV replication by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for the HIV replication cycle.
JULUCA is a fixed-dose combination of dolutegravir, an integrase strand transfer inhibitor (INSTI) that blocks the strand transfer step of retroviral DNA integration essential for HIV replication, and rilpivirine, a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) that non-competitively inhibits HIV-1 reverse transcriptase without inhibiting human cellular DNA polymerases alpha, beta, or gamma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Apretude
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Juluca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (1/12) · Qty limit (11/12)
UnitedHealthcare
Apretude
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Juluca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Apretude
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Juluca
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Apretude Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ApretudeView full Apretude profile
JulucaView full Juluca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.